Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This systematic review and meta-analysis reported that deuruxolitinib is effective for hair regrowth and improving patient-reported outcomes in individuals with moderate to severe alopecia areata, but observed manageable treatment-emergent adverse events such as elevated creatinine kinase levels and headaches, particularly with higher doses.

This case report describes a young girl with trichothiodystrophy and suggests the need for early diagnosis and multidisciplinary interventions for her educational challenges.

This commentary highlights that transgender patients are often dissatisfied with standard hormone replacement therapy for hair-related goals, emphasizing the need for dermatologists to provide informed guidance and tailor treatments.

This study found that Rumex japonicus extract may help reduce symptoms of atopic dermatitis by inhibiting inflammatory responses in both cell cultures and a mouse model.

This study found that daily treatment with ritlecitinib 50 mg over 24 months reduced the number of patients in the highest categories of scalp hair loss, with improvements seen in patient responses over time.

In this study, researchers observed that the skin quality and hair follicle development of Rex rabbits improved when slaughtered in winter compared to summer, with findings suggesting seasonal regulation via multiple signaling pathways affecting fur characteristics.

In this study, researchers at Nottingham Children's Renal Unit found that most pediatric patients switching from Prograf to the generic tacrolimus preparation Adoport maintained stable tacrolimus levels and therapeutic effectiveness, supporting Adoport's use as a cost-saving alternative for the NHS.

This case report describes a 3-year-old boy with trichothiodystrophy, highlighting specific MRI findings of diffuse dysmyelination and osteosclerosis that may be unique to the disorder.

This case report suggests that methotrexate therapy for psoriasis may lead to hair regrowth in androgenetic alopecia, potentially due to its effects on testosterone metabolism.

Type I keratin genes are closely linked to the rex locus on mouse chromosome 11, affecting hair development.

This study found that patients receiving active ritlecitinib doses reported greater satisfaction with hair growth compared to placebo, with high agreement observed between clinician evaluations of scalp hair improvement and patient satisfaction through week 48.

This systematic review assessed the off-label use of topical Ruxolitinib cream for various skin conditions and found it effective for lichenoid and granulomatous dermatoses, though results for alopecia areata were inconsistent. The authors indicate that further research is warranted to confirm these findings.

Deuruxolitinib significantly improves hair satisfaction in severe alopecia areata patients.

In this study, a new formulation of all-trans retinoic acid bound to polyvinyl alcohol showed reduced skin inflammation and sustained drug release for up to six days compared to free ATRA in vitro and in vivo.

This study found that 54% of participants with androgenetic alopecia using Ricapil® showed clinical signs of hair follicle reactivation and initial hair regrowth over three months.

This study found no increased frequency of the TNF2 allele in Mexican patients with adverse cutaneous drug reactions mediated by delayed hypersensitivity, suggesting its lower relevance compared to findings in Caucasian populations.

In this study, the reconstructed skin epidermal model derived from hair follicles showed gene expression and enzyme functionality consistent with native human skin, suggesting its viability for studying skin metabolism and potential toxicity of dermo-cosmetic ingredients.

Low-dose Ritlecitinib may help children with stubborn Alopecia Areata.

This study found that Plerixafor, a CXCR4 antagonist, promotes melanogenesis in melanocytes by increasing MITF and tyrosinase expression and enhancing melanocyte migration, and it effectively restores pigmentation in a mouse depigmentation model without toxicity, highlighting its potential for treating pigmentary disorders.

This study reports that long-term treatment with ritlecitinib is generally well tolerated for up to approximately five years in patients aged 12 and older with alopecia areata, with the safety profile aligning with previous data from the ALLEGRO clinical trials.

This research observed that oxytocin receptor agonists WAY267464 and LIT001 increased hair growth-related gene expression in human dermal papilla cells and significantly promoted hair follicle sprouting in vitro, suggesting their potential as hair growth agents targeting OXTR for alopecia treatment.

A new mutation in the TRPS1 gene caused Trichorhinophalangeal syndrome in a 17-year-old, highlighting the need for genetic testing.

This article reviews confocal microscopy findings in trichoepithelioma and desmoplastic trichoepithelioma, noting similarities with histological features, but it provides no new clinical results.

This study found that ALRN-6924, a clinical-stage dual inhibitor, can selectively protect human scalp hair follicles from paclitaxel-induced toxicity and damage by inducing transient cell cycle arrest in healthy cells without affecting cancer cells, potentially reducing chemotherapy-induced alopecia.